FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie ' s Humira (adalimumab) Prescribing Information

NORTH CHICAGO, Ill., March 30, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the inclusion of moderate to severe fingernail psoriasis data in...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news